BioCentury | Dec 18, 2020
Management Tracks

Rim named CEO of Samsung Biologics as Sarepta unveils promotions; plus Coughlin, Iovance, SpringWorks and NodThera

...By Danielle Golovin, Staff Writer Samsung Biologics promoted EVP John Rim to president and CEO. Before joining...
...Oncology Inc. SpringWorks Therapeutics Inc. NodThera Ltd. Repare Therapeutics Inc. Syntimmune Inc. NLR family pyrin domain containing 3 (NLRP3) (NALP3) (CIAS1) Samsung Biologics...
BioCentury | Jul 2, 2020
Finance

SK becomes Korea’s third-largest public healthcare company after $800M IPO

...billion). SK now has the third-largest valuation among healthcare companies trading in South Korea, after Samsung Biologics Co. Ltd....
BioCentury | Jun 8, 2020
Product Development

COVID-19 mAb supplies could fall short of demand

...but warned that it may not be possible to meet demand. Vir has contracted with Samsung BioLogics Co. Ltd....
BioCentury | Apr 16, 2020
Product Development

April 15 Quick Takes: TScan, Novartis team up on TCR therapies and a first for UroGen; plus Aligos, Leo, Madrigal, Merck

...rights to Ontruzant from Samsung Bioepis Co. Ltd., a JV between Biogen Inc. (NASDAQ:BIIB) and Samsung BioLogics Co. Ltd....
BioCentury | Apr 10, 2020
Deals

Amid flurry of COVID-19 deals, Vir turns to Samsung to ramp up manufacturing

...the clinic, Vir has wasted no time securing manufacturing capacity. The biotech Friday partnered with Samsung Biologics...
...VIR-7831 and VIR-7832, which target the spike protein of SARS-CoV-2. Under the $362 million deal, Samsung BioLogics Co. Ltd....
...of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Elizabeth S. Eaton, Staff Writer Vir Biotechnology Inc. Samsung BioLogics Co. Ltd. GlaxoSmithKline...
BioCentury | Nov 19, 2019
Company News

Nov. 19 Company Quick Takes: Medicines Co. gains on buyout rumor; plus Samsung's biosimilar under review and Zelluna-Glycostem

...Ltd. for SB8, a biosimilar of Avastin bevacizumab. The JV between Biogen Inc. (NASDAQ:BIIB) and Samsung BioLogics Co. Ltd....
...cell receptor; VEGF - Vascular endothelial growth factor BioCentury Staff Samsung Bioepis Co. Ltd. Biogen Inc. Merck & Co. Inc. Samsung BioLogics Co. Ltd. Zelluna...
BioCentury | Nov 6, 2019
Company News

Biogen expanding biosimilars deal for eye therapies, anti-TNFs

...NASDAQ:BIIB) will pay $100 million up front to Samsung Bioepis, the JV it shares with Samsung BioLogics Co. Ltd....
...A Washington Editor Steve Usdin contributed to this report. Paul Bonanos, Associate Editor Biogen Inc. Samsung Bioepis Co. Ltd. Samsung BioLogics Co. Ltd....
BioCentury | Mar 22, 2019
Company News

Reports: prosecutors investigate Korea Exchange for Samsung BioLogics IPO

...Korean prosecutors raided Korean Stock Exchange offices after suspecting the exchange eased regulations to allow Samsung BioLogics'...
...according to reports. In November, Korea’s Securities and Futures Commission (SFC) temporarily suspended trading of Samsung BioLogics Co. Ltd....
...disclosure prior to Samsung BioLogics' IPO (see "Samsung BioLogics Trading Suspended After Accounting Violations" ). Chris Lieu, Staff Writer Samsung BioLogics Co. Ltd. Korean...
BioCentury | Feb 15, 2019
Company News

Samsung Bioepis partners with AffaMed, expands biosimilar development in China

...Manager of Sanofi Pasteur China. Samsung Bioepis is a JV between Biogen Inc. (NASDAQ:BIIB) and Samsung BioLogics Co. Ltd....
BioCentury | Jan 25, 2019
Clinical News

Samsung's Herceptin biosimilar gains U.S. approval

...Samsung Bioepis' Trastuzumab Biosimilar" ). Samsung Bioepis is a JV between Biogen Inc. (NASDAQ:BIIB) and Samsung BioLogics Co. Ltd....
Items per page:
1 - 10 of 99
BioCentury | Dec 18, 2020
Management Tracks

Rim named CEO of Samsung Biologics as Sarepta unveils promotions; plus Coughlin, Iovance, SpringWorks and NodThera

...By Danielle Golovin, Staff Writer Samsung Biologics promoted EVP John Rim to president and CEO. Before joining...
...Oncology Inc. SpringWorks Therapeutics Inc. NodThera Ltd. Repare Therapeutics Inc. Syntimmune Inc. NLR family pyrin domain containing 3 (NLRP3) (NALP3) (CIAS1) Samsung Biologics...
BioCentury | Jul 2, 2020
Finance

SK becomes Korea’s third-largest public healthcare company after $800M IPO

...billion). SK now has the third-largest valuation among healthcare companies trading in South Korea, after Samsung Biologics Co. Ltd....
BioCentury | Jun 8, 2020
Product Development

COVID-19 mAb supplies could fall short of demand

...but warned that it may not be possible to meet demand. Vir has contracted with Samsung BioLogics Co. Ltd....
BioCentury | Apr 16, 2020
Product Development

April 15 Quick Takes: TScan, Novartis team up on TCR therapies and a first for UroGen; plus Aligos, Leo, Madrigal, Merck

...rights to Ontruzant from Samsung Bioepis Co. Ltd., a JV between Biogen Inc. (NASDAQ:BIIB) and Samsung BioLogics Co. Ltd....
BioCentury | Apr 10, 2020
Deals

Amid flurry of COVID-19 deals, Vir turns to Samsung to ramp up manufacturing

...the clinic, Vir has wasted no time securing manufacturing capacity. The biotech Friday partnered with Samsung Biologics...
...VIR-7831 and VIR-7832, which target the spike protein of SARS-CoV-2. Under the $362 million deal, Samsung BioLogics Co. Ltd....
...of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Elizabeth S. Eaton, Staff Writer Vir Biotechnology Inc. Samsung BioLogics Co. Ltd. GlaxoSmithKline...
BioCentury | Nov 19, 2019
Company News

Nov. 19 Company Quick Takes: Medicines Co. gains on buyout rumor; plus Samsung's biosimilar under review and Zelluna-Glycostem

...Ltd. for SB8, a biosimilar of Avastin bevacizumab. The JV between Biogen Inc. (NASDAQ:BIIB) and Samsung BioLogics Co. Ltd....
...cell receptor; VEGF - Vascular endothelial growth factor BioCentury Staff Samsung Bioepis Co. Ltd. Biogen Inc. Merck & Co. Inc. Samsung BioLogics Co. Ltd. Zelluna...
BioCentury | Nov 6, 2019
Company News

Biogen expanding biosimilars deal for eye therapies, anti-TNFs

...NASDAQ:BIIB) will pay $100 million up front to Samsung Bioepis, the JV it shares with Samsung BioLogics Co. Ltd....
...A Washington Editor Steve Usdin contributed to this report. Paul Bonanos, Associate Editor Biogen Inc. Samsung Bioepis Co. Ltd. Samsung BioLogics Co. Ltd....
BioCentury | Mar 22, 2019
Company News

Reports: prosecutors investigate Korea Exchange for Samsung BioLogics IPO

...Korean prosecutors raided Korean Stock Exchange offices after suspecting the exchange eased regulations to allow Samsung BioLogics'...
...according to reports. In November, Korea’s Securities and Futures Commission (SFC) temporarily suspended trading of Samsung BioLogics Co. Ltd....
...disclosure prior to Samsung BioLogics' IPO (see "Samsung BioLogics Trading Suspended After Accounting Violations" ). Chris Lieu, Staff Writer Samsung BioLogics Co. Ltd. Korean...
BioCentury | Feb 15, 2019
Company News

Samsung Bioepis partners with AffaMed, expands biosimilar development in China

...Manager of Sanofi Pasteur China. Samsung Bioepis is a JV between Biogen Inc. (NASDAQ:BIIB) and Samsung BioLogics Co. Ltd....
BioCentury | Jan 25, 2019
Clinical News

Samsung's Herceptin biosimilar gains U.S. approval

...Samsung Bioepis' Trastuzumab Biosimilar" ). Samsung Bioepis is a JV between Biogen Inc. (NASDAQ:BIIB) and Samsung BioLogics Co. Ltd....
Items per page:
1 - 10 of 99